patients undergoing general anesthesia
Conditions
Interventions
Group A:TCI pump alfentanil to the effect chamber concentration of 90 ng/ml (Maitre model), the concentration gradient is 3 ng/ml
Group R:TCI pump remifentanil to the effect chamber concentration of 3 ng/ml (Minto model), the concentration gradient is 0.3 ng/ml
Group E:After esketamine 0.3 mg/kg intravenously, TCI pump remifentanil to the effect chamber concentration of 3 ng/ml (Minto model), the concentration gradient is 0.3 ng/ml
Sponsors
Chongqing University Fuling Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-65 years old (including 18 and 65 years old); 2. ASA I-II level; 3. 18 kg/m^2 <= BMI <= 30 kg/m^2; 4. Patients undergoing elective general anesthesia (only tracheal intubation and mechanical ventilation, 1 h <= estimated anesthesia time <= 2.5 h); 5. Subjects volunteered to participate in this experiment and signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. There are contraindications to general anesthesia; 2. Besides general anesthesia, other anesthesia methods should be combined; 3. Patients who are known to be intolerant or allergic to escitalopram, alfentanil, remifentanil, propofol and rocuronium bromide; 4. Abnormal coagulation function (PT or PT-INR >= 1.5 × ULN), bleeding tendency (such as active digestive tract ulcer) or being treated with anticoagulation or thrombolysis; 5. Abnormal liver function (ALT and/or AST >= 1.5 × ULN, TBIL >= 1.5 × ULN); 6. Abnormal renal function, BUN >= 1.5 × ULN, and serum creatinine exceeding the upper limit of normal value; 7. Patients with severe cardiovascular history (such as coronary atherosclerotic heart disease, heart failure, arrhythmia to be treated, etc.), unstable angina pectoris, or myocardial infarction in the last 6 months; 8. Those whose blood pressure has not been satisfactorily controlled (SBP >= 160 mmHg and/or DBP >= 110 mmhg in screening period); 9. Those who have a history of craniocerebral injury, intracranial hypertension, cerebral aneurysm and cerebrovascular accident; 10. Diabetic patients whose blood sugar has not been satisfactorily controlled (fasting blood sugar >= 11.1 mmol/L in screening period); 11. Patients with a history of hyperthyroidism; 12. Patients with elevated intraocular pressure (such as glaucoma) or history of penetrating eye injury; 13. Patients with mental diseases (schizophrenia, mania, bipolar disorder, insanity, etc.) and long-term history of taking psychotropic drugs and cognitive dysfunction; 14. Patients with a history of asthma; 15. Patients who are judged to have difficulty in respiratory management (the modified Markov score is grade IV); 16. History of drug abuse and alcohol abuse within 2 years before the start of the screening period: alcohol abuse is defined as drinking more than 14 times/week on a regular basis (1 time = 150 ml wine or 360 ml beer or 45 ml spirits); 17. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| adrenergic response; | — |
Countries
China
Contacts
Public ContactXue Yun
Chongqing University Fuling Hospital
Outcome results
None listed